Sesen Bio Announces Acceptance of Analytical Comparability Plan by the US Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer - Associated Press https://t.co/1LkBwvT1al

Sesen Bio Announces Acceptance of Analytical Comparability Plan by the US Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer - Associated Press https://t.co/1LkBwvT1al

— IDRO (@IDROOhio) May 21, 2019

from Twitter https://twitter.com/IDROOhio

May 21, 2019 at 03:02AM